Portfolio company
Taveren Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops oncology drug candidates that reactivate natural tumour suppressors for pharmaceutical partners and cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
AdoRx Therapeutics
This company develops small-molecule adenosine receptor antagonists for pharmaceutical partners to treat cancer by disrupting immune evasion in the tumour microenvironment.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Tacalyx
This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.
Momentous Therapeutics
This company develops pan-cancer drugs and therapeutic treatments for the pharmaceutical industry to address challenging biological targets.
Taurus Oncology
Taurus Oncology develops in-licensed Asian oncology assets into clinical-stage medicines for global biopharmaceutical companies and patients.